{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Affimed NV
Is Affimed NV technically bullish or bearish?
As of June 4, 2025, Affimed NV's trend is mildly bearish, with mixed signals from moving averages, MACD, and RSI, indicating a lack of strong conviction in either direction.
Who are in the management team of Affimed NV?
As of March 2022, the management team of Affimed NV includes Dr. Thomas Hecht (Chairman) and five independent members: Dr. Bernhard Ehmer, Dr. Ulrich Grau, Mr. Berndt Modig, Dr. Mathieu Simon, and Dr. Ferdinand Verdonck, who oversee the company's strategic direction and governance.
What does Affimed NV do?
Affimed N.V. is a clinical-stage biopharmaceutical company focused on developing cancer immunotherapies, currently reporting no net sales and a net loss of $17 million as of September 2024, with a market cap of $1.26 million. The company has a negative return on equity and does not pay dividends.
How big is Affimed NV?
As of Jun 18, Affimed NV has a market capitalization of 1.26 million, with net sales of 0.95 million and a net profit of -75.80 million over the last four quarters. The company reported shareholder's funds of 63.86 million and total assets of 107.32 million as of Dec 23.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
